TransCode Therapeutics, Inc. (RNAZ) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
TransCode Therapeutics, Inc. (RNAZ) Earnings Overview
As of June 23, 2026, TransCode Therapeutics, Inc. (RNAZ) reported trailing twelve-month net income of -$40M, reflecting -11.6% year-over-year growth. The company earned $-44.02 per diluted share over the past four quarters.
Looking at the long-term picture, RNAZ's historical earnings data spans multiple years. The company achieved its highest annual net income of -$453,440 in fiscal 2018.
TransCode Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARWR (-$301M net income, -0.2% margin), NTLA (-$395M net income, -609.9% margin), SRPT ($65M net income, -32.5% margin), RNAZ has comparable earnings metrics. Compare RNAZ vs ARWR →
RNAZ Earnings vs Peers
Earnings metrics vs comparable public companies
RNAZ Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$35M | -106.9% | -$28M | $-52.59 | - | - |
| 2024 | -$17M | +9.7% | -$16M | $-47.14 | - | - |
| 2023 | -$19M | -5.6% | -$19M | $-3453.53 | - | - |
| 2022 | -$18M | -156.7% | -$19M | $-1080.00 | - | - |
| 2021 | -$7M | -192.0% | -$6M | $-648.00 | - | - |
| 2020 | -$2M | -286.0% | $-726,604 | $-293.76 | - | - |
| 2019 | $-607,212 | -33.9% | $-456,865 | $-72.00 | - | - |
| 2018 | $-453,440 | - | $-383,996 | $-2359.09 | - | - |
Download Data
Export RNAZ earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RNAZ — Frequently Asked Questions
Quick answers to the most common questions about buying RNAZ stock.
What is RNAZ earnings per share (EPS)?
RNAZ trailing twelve-month (TTM) diluted EPS is $-44.02, reflecting -11.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is TransCode Therapeutics, Inc.'s net income?
TransCode Therapeutics, Inc. (RNAZ) trailing twelve-month net income is $-40M as of 2025. Earnings declined -11.6% year-over-year.
Is RNAZ profitable?
RNAZ is not currently profitable on a TTM basis, reporting a net loss of $-40M. Net margin is N/A. Investors should monitor for a return to profitability.
What is RNAZ's earnings growth rate?
RNAZ compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are RNAZ's profit margins?
TransCode Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -833.5%.
Is RNAZ growing earnings?
RNAZ earnings are declining — EPS fell -11.6% year-over-year. TTM net income dropped to $-40M. This contrasts with the 5-year CAGR of N/A.
What was RNAZ's best earnings year?
TransCode Therapeutics, Inc.'s highest annual net income on record is $-453440.00, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were RNAZ's earnings last quarter?
RNAZ's most recent reported quarter was Q1 2026. Net income was $-18M with diluted EPS of $-21.28. For a full breakdown of all quarters, see the quarterly earnings table on this page.